RE:Combination drugs EnriqueSuave ... Nice catch
The data got an enthusiastic reception from the AUA audience, who used terms such as "excellent," "fantastic," and "terrific" to describe the preliminary results. However, one British urologist expressed reservations about the urology community's willingness to venture into immunotherapy.
"I have tried to launch some immunotherapy trials for non-muscle-invasive bladder cancer in the U.K., and the anxiety among urologists is such that they think pembrolizumab is not for them, but for oncologists to deliver," said the unidentified speaker.
And check the burden immunotherapy adds on the healthcare system, something our Theralase treatment doesn't require:
Acknowledging that immunotherapy is uncharted territory for many urologists, Li said collaboration between urologists and oncologists is essential, regardless of who administers the immunotherapy.
"Most of the centers that participated [in the trial] were tertiary referral centers with a very close collaboration between the urologists and the medical oncologists," said Li. "The close relationship was required not only to administer the drugs but also to monitor the patients. We had patients with immune-related pneumonitis, and that was the first time I had seen it. I got a lot of help from my medical oncology colleagues."